PDGFRA and neoplasm: Sunitinib (SU11248) was a logical agent to study, since it is an orally bioavailable inhibitor affecting RTKs involved in tumor proliferation and angio-genesis, including VEGFR-1, -2, and -3, and PDGFR-α and -β.